Posted by Michael Wonder on 29 Dec 2021
Valemetostat new drug application submitted in Japan for treatment of patients with adult T-cell leukaemia/lymphoma
28 December 2021 - Submission of orphan drug designated valemetostat based on pivotal phase 2 trial in patients with relapsed/refractory adult T-cell leukaemia/lymphoma.
Daiichi Sankyo today announced that it has submitted a new drug application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukaemia/lymphoma.
